Obstetrics & Gynecology in Brandywine, MD
3 verified obstetrics & gynecology doctors in Brandywine.
OB/GYNs provide women's reproductive health care, including pregnancy, childbirth, and gynecologic conditions.
NPPES tenure ≠ clinical experience. "Years on NPPES" is time since the physician first registered a National Provider Identifier, not time practicing medicine. Verify current license status with the state medical board.
Dr. C. Emmanuel Ayers, MD
Obstetrics & Gynecology
CMS Open Payments· $56.21 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$56.21
Total received
3
Transactions
1
Paying companies
Top paying companies
Among the 47,072 obstetrics & gynecology doctors we've analyzed, about 47% received any industry payment (median $178 among those who did). This doctor's total ranks around the 65th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US obstetrics & gynecology doctors.
Payments to C. Emmanuel Ayers do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Lucie Moravia, DO
Obstetrics & Gynecology
CMS Open Payments· $19.50 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$19.50
Total received
1
Transactions
1
Paying companies
Top paying companies
Among the 47,072 obstetrics & gynecology doctors we've analyzed, about 47% received any industry payment (median $178 among those who did). This doctor's total ranks around the 57th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US obstetrics & gynecology doctors.
Payments to Lucie Moravia do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Anita Jones, MD
Obstetrics & Gynecology
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.